RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes

by Dieussaert I. et al.

The authors conducted a phase 3 trial involving pregnant women 18 to 49 years of age to assess the efficacy and safety of RSVPreF3-Mat. The results of this trial, in which enrollment was stopped early because of safety concerns, suggest that the risks of any and severe medically assessed RSV-associated lower respiratory tract disease among infants were lower with the candidate maternal RSV vaccine than with placebo but that the risk of preterm birth was higher with the candidate vaccine.

4th April 2024 • comment

Association of Discrimination and Health Care Experiences With Incomplete Infant Vaccination During COVID-19

by Preis et al

This observational analysis explores how the COVID-19 pandemic contributed to a decrease in infant vaccinations.

23rd February 2022 • comment

A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and fertility

by Wesselink et al

This study examined the associations of COVID-19 vaccination and SARS-CoV-2 infection with fertility among couples trying to conceive spontaneously using data from an internet-based preconception cohort study. Findings indicate that male SARS-CoV-2 infection may be associated with a short-term decline in fertility and that COVID-19 vaccination does not impair fertility in either partner.

8th February 2022 • comment